Dynamic Contrast-Enhanced MRI Confirms Rapid And Sustained Improvement Of Rheumatoid Arthritis Induced By Tocilizumab Treatment: An Italian Multicentre Study

Marco A Cimmino,1 Massimiliano Parodi,1 Francesca Barbieri,1 Stefano Bombardieri,2 Giuseppe Zampogna,1 Annamaria Iagnocco,3 Alberto Batticciotto,4 Luca Maria Sconfienza,5,6 Luigi Sinigaglia,7 Fabrizio De Benedetti,8 Fabiola Atzeni,9 Piercarlo Sarzi-Puttini10 1Research Laboratory and Academic Divisio...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Cimmino MA, Parodi M, Barbieri F, Bombardieri S, Zampogna G, Iagnocco A, Batticciotto A, Sconfienza LM, Sinigaglia L, De Benedetti F, Atzeni F, Sarzi-Puttini P
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2020
Materias:	tocilizumab rheumatoid arthritis wrist synovitis low-field mri dedicated mri Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/f35cd1b030ce468687ce48c87f7ba46c
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:f35cd1b030ce468687ce48c87f7ba46c
record_format	dspace
spelling	oai:doaj.org-article:f35cd1b030ce468687ce48c87f7ba46c2021-12-02T09:18:54ZDynamic Contrast-Enhanced MRI Confirms Rapid And Sustained Improvement Of Rheumatoid Arthritis Induced By Tocilizumab Treatment: An Italian Multicentre Study1177-5491https://doaj.org/article/f35cd1b030ce468687ce48c87f7ba46c2020-02-01T00:00:00Zhttps://www.dovepress.com/dynamic-contrast-enhanced-mri-confirms-rapid-and-sustained-improvement-peer-reviewed-article-BTThttps://doaj.org/toc/1177-5491Marco A Cimmino,1 Massimiliano Parodi,1 Francesca Barbieri,1 Stefano Bombardieri,2 Giuseppe Zampogna,1 Annamaria Iagnocco,3 Alberto Batticciotto,4 Luca Maria Sconfienza,5,6 Luigi Sinigaglia,7 Fabrizio De Benedetti,8 Fabiola Atzeni,9 Piercarlo Sarzi-Puttini10 1Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genoa, Genoa, Italy; 2Rheumatology Unit, Santa Chiara Hospital, University of Pisa, Pisa, Italy; 3Academic Rheumatology Centre, Università degli Studi di Torino, Turin, Italy; 4Rheumatology Unit ASST-Settelaghi, Ospedale di Circolo – Fondazione Macchi, Varese, Varese, Italy; 5IRCCS Istituto Ortopedico Galeazzi, Milan, Italy; 6Dipartimento di Scienze Biomediche per la Salute, Università degli Studi di Milano, Milan, Italy; 7Rheumatology Unit, G. Pini Hospital, Milan, Italy; 8Division of Rheumatology, IRCCS, Bambin Gesù Paediatric Hospital, Rome, Italy; 9Rheumatology Unit, University of Messina, Messina, Italy; 10Rheumatology Unit, L. Sacco University Hospital, Milan, ItalyCorrespondence: Piercarlo Sarzi-PuttiniReumatology Department, L. Sacco University Hospital, ASST Fatebenefratelli – Sacco, Via G.B. Grassi, 74, Milan 20157, ItalyTel +39 02 39042208Email piercarlo.sarziputtini@gmail.comObjective: This open-label study evaluated the effects of combined tocilizumab (TCZ) and disease-modifying antirheumatic drugs (DMARDs) on magnetic resonance imaging (MRI) changes in synovial membrane enhancement, bone marrow edema (BME), and erosions in the wrist and hand joints of rheumatoid arthritis (RA) patients inadequately responding to DMARDs alone.Methods: The efficacy of intravenous TCZ 8 mg/kg administered every four weeks for 48 weeks was evaluated on six occasions. The primary endpoints were the changes in the extent and degree of wrist synovitis as measured using the RA MRI Score (RAMRIS) and dynamic, gadolinium-enhanced 0.2T MRI (DCE-MRI). A number of different parameters of DCE-MRI were evaluated.Results: Fifty-eight patients were treated, eight of whom (13.8%) discontinued the study prematurely. The mean RAMRIS significantly decreased after two weeks and the decrease was maintained for up to 48 weeks. By week 4, the mean RAMRIS synovitis score had significantly decreased from baseline (− 0.804± 1.575; p=0.018), but not the mean early enhancement (REE) or relative enhancement (RE). However, there were significant decreases in RE at week 24, in REE and Ntotal (total number of enhancing voxels)IRE (initial rate of enhancement) at weeks 12, 24 and 48, and in NtotalME (maximal enhancement) at weeks 24 and 48. Mean BME decreased from baseline to week 48, and bone erosions did not progress. The patients’ clinical parameters significantly improved from baseline until week 48.Conclusion: TCZ in combination with DMARDs improved wrist synovitis, BME and clinical parameters, without any progression in bone erosions. The RAMRIS for synovitis rapidly improved from as early as two weeks after the first TCZ infusion. (Funded by F. Hoffmann–La Roche; ACTRACE EudraCT No. 2009 012185-32).Keywords: tocilizumab, rheumatoid arthritis, wrist, synovitis, low-field MRI, dedicated MRICimmino MAParodi MBarbieri FBombardieri SZampogna GIagnocco ABatticciotto ASconfienza LMSinigaglia LDe Benedetti FAtzeni FSarzi-Puttini PDove Medical Pressarticletocilizumabrheumatoid arthritiswristsynovitislow-field mridedicated mriMedicine (General)R5-920ENBiologics: Targets & Therapy, Vol Volume 14, Pp 13-21 (2020)
institution	DOAJ
collection	DOAJ
language	EN
topic	tocilizumab rheumatoid arthritis wrist synovitis low-field mri dedicated mri Medicine (General) R5-920
spellingShingle	tocilizumab rheumatoid arthritis wrist synovitis low-field mri dedicated mri Medicine (General) R5-920 Cimmino MA Parodi M Barbieri F Bombardieri S Zampogna G Iagnocco A Batticciotto A Sconfienza LM Sinigaglia L De Benedetti F Atzeni F Sarzi-Puttini P Dynamic Contrast-Enhanced MRI Confirms Rapid And Sustained Improvement Of Rheumatoid Arthritis Induced By Tocilizumab Treatment: An Italian Multicentre Study
description	Marco A Cimmino,1 Massimiliano Parodi,1 Francesca Barbieri,1 Stefano Bombardieri,2 Giuseppe Zampogna,1 Annamaria Iagnocco,3 Alberto Batticciotto,4 Luca Maria Sconfienza,5,6 Luigi Sinigaglia,7 Fabrizio De Benedetti,8 Fabiola Atzeni,9 Piercarlo Sarzi-Puttini10 1Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genoa, Genoa, Italy; 2Rheumatology Unit, Santa Chiara Hospital, University of Pisa, Pisa, Italy; 3Academic Rheumatology Centre, Università degli Studi di Torino, Turin, Italy; 4Rheumatology Unit ASST-Settelaghi, Ospedale di Circolo – Fondazione Macchi, Varese, Varese, Italy; 5IRCCS Istituto Ortopedico Galeazzi, Milan, Italy; 6Dipartimento di Scienze Biomediche per la Salute, Università degli Studi di Milano, Milan, Italy; 7Rheumatology Unit, G. Pini Hospital, Milan, Italy; 8Division of Rheumatology, IRCCS, Bambin Gesù Paediatric Hospital, Rome, Italy; 9Rheumatology Unit, University of Messina, Messina, Italy; 10Rheumatology Unit, L. Sacco University Hospital, Milan, ItalyCorrespondence: Piercarlo Sarzi-PuttiniReumatology Department, L. Sacco University Hospital, ASST Fatebenefratelli – Sacco, Via G.B. Grassi, 74, Milan 20157, ItalyTel +39 02 39042208Email piercarlo.sarziputtini@gmail.comObjective: This open-label study evaluated the effects of combined tocilizumab (TCZ) and disease-modifying antirheumatic drugs (DMARDs) on magnetic resonance imaging (MRI) changes in synovial membrane enhancement, bone marrow edema (BME), and erosions in the wrist and hand joints of rheumatoid arthritis (RA) patients inadequately responding to DMARDs alone.Methods: The efficacy of intravenous TCZ 8 mg/kg administered every four weeks for 48 weeks was evaluated on six occasions. The primary endpoints were the changes in the extent and degree of wrist synovitis as measured using the RA MRI Score (RAMRIS) and dynamic, gadolinium-enhanced 0.2T MRI (DCE-MRI). A number of different parameters of DCE-MRI were evaluated.Results: Fifty-eight patients were treated, eight of whom (13.8%) discontinued the study prematurely. The mean RAMRIS significantly decreased after two weeks and the decrease was maintained for up to 48 weeks. By week 4, the mean RAMRIS synovitis score had significantly decreased from baseline (− 0.804± 1.575; p=0.018), but not the mean early enhancement (REE) or relative enhancement (RE). However, there were significant decreases in RE at week 24, in REE and Ntotal (total number of enhancing voxels)IRE (initial rate of enhancement) at weeks 12, 24 and 48, and in NtotalME (maximal enhancement) at weeks 24 and 48. Mean BME decreased from baseline to week 48, and bone erosions did not progress. The patients’ clinical parameters significantly improved from baseline until week 48.Conclusion: TCZ in combination with DMARDs improved wrist synovitis, BME and clinical parameters, without any progression in bone erosions. The RAMRIS for synovitis rapidly improved from as early as two weeks after the first TCZ infusion. (Funded by F. Hoffmann–La Roche; ACTRACE EudraCT No. 2009 012185-32).Keywords: tocilizumab, rheumatoid arthritis, wrist, synovitis, low-field MRI, dedicated MRI
format	article
author	Cimmino MA Parodi M Barbieri F Bombardieri S Zampogna G Iagnocco A Batticciotto A Sconfienza LM Sinigaglia L De Benedetti F Atzeni F Sarzi-Puttini P
author_facet	Cimmino MA Parodi M Barbieri F Bombardieri S Zampogna G Iagnocco A Batticciotto A Sconfienza LM Sinigaglia L De Benedetti F Atzeni F Sarzi-Puttini P
author_sort	Cimmino MA
title	Dynamic Contrast-Enhanced MRI Confirms Rapid And Sustained Improvement Of Rheumatoid Arthritis Induced By Tocilizumab Treatment: An Italian Multicentre Study
title_short	Dynamic Contrast-Enhanced MRI Confirms Rapid And Sustained Improvement Of Rheumatoid Arthritis Induced By Tocilizumab Treatment: An Italian Multicentre Study
title_full	Dynamic Contrast-Enhanced MRI Confirms Rapid And Sustained Improvement Of Rheumatoid Arthritis Induced By Tocilizumab Treatment: An Italian Multicentre Study
title_fullStr	Dynamic Contrast-Enhanced MRI Confirms Rapid And Sustained Improvement Of Rheumatoid Arthritis Induced By Tocilizumab Treatment: An Italian Multicentre Study
title_full_unstemmed	Dynamic Contrast-Enhanced MRI Confirms Rapid And Sustained Improvement Of Rheumatoid Arthritis Induced By Tocilizumab Treatment: An Italian Multicentre Study
title_sort	dynamic contrast-enhanced mri confirms rapid and sustained improvement of rheumatoid arthritis induced by tocilizumab treatment: an italian multicentre study
publisher	Dove Medical Press
publishDate	2020
url	https://doaj.org/article/f35cd1b030ce468687ce48c87f7ba46c
work_keys_str_mv	AT cimminoma dynamiccontrastenhancedmriconfirmsrapidandsustainedimprovementofrheumatoidarthritisinducedbytocilizumabtreatmentanitalianmulticentrestudy AT parodim dynamiccontrastenhancedmriconfirmsrapidandsustainedimprovementofrheumatoidarthritisinducedbytocilizumabtreatmentanitalianmulticentrestudy AT barbierif dynamiccontrastenhancedmriconfirmsrapidandsustainedimprovementofrheumatoidarthritisinducedbytocilizumabtreatmentanitalianmulticentrestudy AT bombardieris dynamiccontrastenhancedmriconfirmsrapidandsustainedimprovementofrheumatoidarthritisinducedbytocilizumabtreatmentanitalianmulticentrestudy AT zampognag dynamiccontrastenhancedmriconfirmsrapidandsustainedimprovementofrheumatoidarthritisinducedbytocilizumabtreatmentanitalianmulticentrestudy AT iagnoccoa dynamiccontrastenhancedmriconfirmsrapidandsustainedimprovementofrheumatoidarthritisinducedbytocilizumabtreatmentanitalianmulticentrestudy AT batticciottoa dynamiccontrastenhancedmriconfirmsrapidandsustainedimprovementofrheumatoidarthritisinducedbytocilizumabtreatmentanitalianmulticentrestudy AT sconfienzalm dynamiccontrastenhancedmriconfirmsrapidandsustainedimprovementofrheumatoidarthritisinducedbytocilizumabtreatmentanitalianmulticentrestudy AT sinigaglial dynamiccontrastenhancedmriconfirmsrapidandsustainedimprovementofrheumatoidarthritisinducedbytocilizumabtreatmentanitalianmulticentrestudy AT debenedettif dynamiccontrastenhancedmriconfirmsrapidandsustainedimprovementofrheumatoidarthritisinducedbytocilizumabtreatmentanitalianmulticentrestudy AT atzenif dynamiccontrastenhancedmriconfirmsrapidandsustainedimprovementofrheumatoidarthritisinducedbytocilizumabtreatmentanitalianmulticentrestudy AT sarziputtinip dynamiccontrastenhancedmriconfirmsrapidandsustainedimprovementofrheumatoidarthritisinducedbytocilizumabtreatmentanitalianmulticentrestudy
_version_	1718398220077367296

Dynamic Contrast-Enhanced MRI Confirms Rapid And Sustained Improvement Of Rheumatoid Arthritis Induced By Tocilizumab Treatment: An Italian Multicentre Study

Ejemplares similares